Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Single nucleotide polymorphisms in NOS2A and NOS3 genes are not associated with treatment response of non-small cell lung cancer patients following the definitive radiochemotherapy.

Authors
  • Zhang, J
  • Li, B S
  • Zhou, C C
  • Yu, H Y
  • Ding, X P
  • Sun, M P
  • Liu, H
  • Yu, G Q
  • Li, H S
  • Huang, W
Type
Published Article
Journal
Neoplasma
Publication Date
Jan 01, 2012
Volume
59
Issue
6
Pages
631–640
Identifiers
DOI: 10.4149/neo_2012_080
PMID: 22862164
Source
Medline
License
Unknown

Abstract

Nitric oxide (NO), is endogenously synthesized from L-arginine by nitric oxide synthase (NOS), exhibits a dual role in sensitivity to radiotherapy and chemotherapy of cancer cells. The aim of this study was to evaluate the influence of polymorphisms in NOS genes on treatment response of non-small-cell lung cancer (NSCLC) patients after radiochemotherapy. A cohort of 198 NSCLC patients treated with radiochemotherapy between 2009 and 2011 were included in this study. Genotyping analyses of 35 SNPs ( NOS2A, 21 and NOS3, 14) in each sample were conducted by using the Sequenom MassArray system. Unconditional logistic regression was performed to assess the association between treatment response and each genotype while adjusting or not for other covariates. Of 198 patients, 87 (43.9%) had objective responses, and 111(56.1%) did not respond. We observed no significant associations between treatment response and each genotype. While adjusting for other covariates, the associations were also not significant. Our results suggest that genetic variations within the NOS2A and NOS3 genes may not influence the treatment response in NSCLC patients with radiochemotherapy. Future studies in this problem are required to confirm our findings.

Report this publication

Statistics

Seen <100 times